US Patent

US11827600 — Crystalline forms of trofinetide

Method of Use · Assigned to Acadia Pharmaceuticals Inc · Expires 2042-07-12 · 16y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects crystalline forms of trofinetide and methods of making and using them to treat a disease, condition, or disorder in a subject.

USPTO Abstract

This disclosure provides crystalline forms of trofinetide and trofinetide hydrate, pharmaceutical compositions comprising crystalline forms of trofinetide and trofinetide hydrate, methods of making crystalline forms of trofinetide or trofinetide hydrate, and methods of treating a disease, condition, or disorder in a subject comprising administering a composition comprising crystalline forms of trofinetide or trofinetide hydrate to the subject.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-3556 — Daybue
U-3556 — Daybue
U-3556 — Daybue
U-3556 — Daybue

Patent Metadata

Patent number
US11827600
Jurisdiction
US
Classification
Method of Use
Expires
2042-07-12
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Acadia Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.